Number of patients (% of study group) | |||
---|---|---|---|
240 mg dosage strength | 120 mg dosage strength | < 120 mg dosage strength | |
Number of patients | 430 | 7,070 | 6,310 |
Medical specialty of initial prescriber | |||
General practitioner | 182 (42.3) | 3,230 (45.7) | 2,978 (47.2) |
Neurologist | 139 (32.3) | 2,038 (28.8) | 887 (14.1) |
Internist | 56 (13.0) | 950 (13.4) | 896 (14.2) |
Other | 53 (12.3) | 852 (12.1) | 1,549 (24.5) |
Region of the initial prescriber | |||
Western Germany | 299 (69.5) | 5,499 (77.8) | 5,500 (87.2) |
Eastern Germany | 131 (30.5) | 1,571 (22.2) | 810 (12.8) |
Insurance membership status | |||
Retired | 353 (82.1) | 5,814 (82.2) | 4,687 (74.3) |
Mandatory member | 62 (14.4) | 1,029 (14.6) | 994 (15.8) |
Family member | 15 (3.5) | 227 (3.2) | 629 (10.0) |
Pre-treatment 180 days prior to index date with | |||
Antidepressants | 181 (42.1) | 3,136 (44.4) | 2,395 (38.0) |
Antidementia drugs | 54 (12.6) | 782 (11.1) | 505 (8.0) |
Nootropics | 24 (5.6) | 379 (5.4) | 236 (3.7) |
Antivertigo preparations (betahistine/flunarizine/cinnarizine) | 50 (11.6) | 720 (10.2) | 639 (10.1) |
Pentoxifylline | 16 (3.7) | 372 (5.3) | 366 (5.8) |
Drugs for treatment of peripheral arterial occlusive disease (cilostazol/naftidrofuryl) | 16 (3.7) | 189 (2.7) | 181 (2.9) |
≥ 5 different ATC third level drugs within 180 days prior to index date | 357 (83.0) | 5,850 (82.7) | 5,023 (79.6) |
Patients with follow-up prescription | 227 (52.8) | 3,202 (45.3) | 2,154 (34.1) |